Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 70 years old
- People who have been diagnosed with multiple myeloma (a type of blood cancer) confirmed through a bone marrow test
- People who are planned to be treated in hospital with a combination therapy called RVd (a standard drug treatment for multiple myeloma)
- People who are expected to be able to complete at least 3 to 4 rounds of this treatment
Who may not be able to join:
- People who have also been diagnosed with a condition called myocardial amyloidosis (a disease where abnormal proteins build up in the heart) or other forms of widespread amyloidosis affecting the body
- People with serious heart conditions, such as a previous heart attack, heart failure, or who have had heart surgery such as a bypass or heart valve replacement
- People with serious heart rhythm problems, such as atrial fibrillation (an irregular heartbeat)
- People whose heart ultrasound (echocardiogram) images are not clear enough to assess properly
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0531-82166271
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impaired systolic function of left ventricle or potential myocardial injury; Impaired systolic function of left ventricle
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.